These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Gene therapy for infectious diseases. Bunnell BA; Morgan RA Clin Microbiol Rev; 1998 Jan; 11(1):42-56. PubMed ID: 9457428 [TBL] [Abstract][Full Text] [Related]
14. Antisense inhibition of virus infections. Kilkuskie RE; Field AK Adv Pharmacol; 1997; 40():437-83. PubMed ID: 9217933 [TBL] [Abstract][Full Text] [Related]
15. In vitro inhibition of hepatitis C virus gene expression by chemically modified antisense oligodeoxynucleotides. Vidalin O; Major ME; Rayner B; Imbach JL; Trépo C; Inchauspé G Antimicrob Agents Chemother; 1996 Oct; 40(10):2337-44. PubMed ID: 8891141 [TBL] [Abstract][Full Text] [Related]
16. Targeting hepatitis B therapy to the liver. Clinical pharmacokinetic considerations. Rensen PC; de Vrueh RL; van Berkel TJ Clin Pharmacokinet; 1996 Aug; 31(2):131-55. PubMed ID: 8853935 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of duck hepatitis B virus replication by 2',3'-dideoxy-3'-fluoroguanosine in vitro and in vivo. Hafkemeyer P; Keppler-Hafkemeyer A; al Haya MA; von Janta-Lipinski M; Matthes E; Lehmann C; Offensperger WB; Offensperger S; Gerok W; Blum HE Antimicrob Agents Chemother; 1996 Mar; 40(3):792-4. PubMed ID: 8851615 [TBL] [Abstract][Full Text] [Related]
18. Oligodeoxynucleotides enhance lipopolysaccharide-stimulated synthesis of tumor necrosis factor: dependence on phosphorothioate modification and reversal by heparin. Hartmann G; Krug A; Waller-Fontaine K; Endres S Mol Med; 1996 Jul; 2(4):429-38. PubMed ID: 8827713 [TBL] [Abstract][Full Text] [Related]